Form 4: Apimeds Pharmaceuticals Director, Elona Kogan, Reports Stock Option Grant

Director Elona Kogan reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc.

Summary

• Elona Kogan, a director of Apimeds Pharmaceuticals US, Inc., filed a Form 4.
• The report details the acquisition of stock options.
• Kogan acquired options to purchase 5,780 shares of common stock at an exercise price of $1.73 per share on May 16, 2025.
• The options vest fully on May 16, 2026, and expire on May 16, 2035.
• Following the transaction, Kogan directly owns options for 5,780 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the company's future performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, stock options, director, Apimeds Pharmaceuticals, beneficial ownership, Elona Kogan